HC Wainwright Reaffirms “Buy” Rating for GH Research (NASDAQ:GHRS)

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRSFree Report) in a report issued on Monday,Benzinga reports. The firm currently has a $40.00 price target on the stock.

Separately, Canaccord Genuity Group reduced their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

Read Our Latest Report on GHRS

GH Research Trading Down 0.2 %

GHRS stock opened at $8.81 on Monday. The firm has a market cap of $458.37 million, a PE ratio of -11.15 and a beta of 0.84. GH Research has a 1 year low of $6.00 and a 1 year high of $14.99. The company has a fifty day simple moving average of $8.41 and a 200 day simple moving average of $8.94.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. raised its position in shares of GH Research PLC (NASDAQ:GHRSFree Report) by 1.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors.

About GH Research

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Further Reading

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.